Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [Studio randomizzato di fase III sull'ottimizzazione della combinazione di bevacizumab con FOLFOX/OXXEL nel trattamento dei pazienti affetti da carcinoma del colon-retto metastatico]

Trial Profile

Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [Studio randomizzato di fase III sull'ottimizzazione della combinazione di bevacizumab con FOLFOX/OXXEL nel trattamento dei pazienti affetti da carcinoma del colon-retto metastatico]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Capecitabine; Fluorouracil; Levofolinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms OBELICS
  • Most Recent Events

    • 11 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 05 Jun 2018 Results (n=230) assessing the efficacy and tolerability of bevacizumab administered prior to or at the same time as the mFOLFOX/OXXEL chemotherapy regimen, containing oxaliplatin, folinic acid, fluorouracil, and capecitabine, in patients with colorectal adenomas, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Sep 2017 Primary endpoint (Objective Response rate) has not been met, as per results presented at the 42nd European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top